These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The co-drug of conjugated hydroquinone and azelaic acid to enhance topical skin targeting and decrease penetration through the skin. Hsieh PW; Al-Suwayeh SA; Fang CL; Lin CF; Chen CC; Fang JY Eur J Pharm Biopharm; 2012 Jun; 81(2):369-78. PubMed ID: 22469554 [TBL] [Abstract][Full Text] [Related]
4. Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid. Hsieh PW; Chen WY; Aljuffali IA; Chen CC; Fang JY Curr Med Chem; 2013; 20(32):4080-92. PubMed ID: 23931279 [TBL] [Abstract][Full Text] [Related]
5. Effect of emulsifiers and their liquid crystalline structures in emulsions on dermal and transdermal delivery of hydroquinone, salicylic acid and octadecenedioic acid. Otto A; Wiechers JW; Kelly CL; Dederen JC; Hadgraft J; du Plessis J Skin Pharmacol Physiol; 2010; 23(5):273-82. PubMed ID: 20484969 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and Characterization of a New Hydroquinone Derivative: Disodium p-Phenylene Diisostearyl Diphosphate. Hisama M; Matsuda S; Arai J; Masui K; Yamamura H J Oleo Sci; 2015; 64(9):1033-41. PubMed ID: 26329772 [TBL] [Abstract][Full Text] [Related]
7. Impact of ester promoieties on transdermal delivery of ketorolac. Liu KS; Hsieh PW; Aljuffali IA; Lin YK; Chang SH; Wang JJ; Fang JY J Pharm Sci; 2014 Mar; 103(3):974-86. PubMed ID: 24481782 [TBL] [Abstract][Full Text] [Related]
8. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Boissy RE; Visscher M; DeLong MA Exp Dermatol; 2005 Aug; 14(8):601-8. PubMed ID: 16026582 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. Hamed SH; Sriwiriyanont P; deLong MA; Visscher MO; Wickett RR; Boissy RE J Cosmet Sci; 2006; 57(4):291-308. PubMed ID: 16957809 [TBL] [Abstract][Full Text] [Related]
10. Effect of penetration modifiers on the dermal and transdermal delivery of drugs and cosmetic active ingredients. Otto A; Wiechers JW; Kelly CL; Hadgraft J; du Plessis J Skin Pharmacol Physiol; 2008; 21(6):326-34. PubMed ID: 18832865 [TBL] [Abstract][Full Text] [Related]
11. Azelaic acid-loaded nanoemulsion with hyaluronic acid - a new strategy to treat hyperpigmentary skin disorders. Jacobus Berlitz S; De Villa D; Maschmann Inácio LA; Davies S; Zatta KC; Guterres SS; Külkamp-Guerreiro IC Drug Dev Ind Pharm; 2019 Apr; 45(4):642-650. PubMed ID: 30642209 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. Mendoza CG; Singzon IA; Handog EB Int J Dermatol; 2014 Nov; 53(11):1412-6. PubMed ID: 25265986 [TBL] [Abstract][Full Text] [Related]
13. Regulatory effect of hydroquinone-tetraethylene glycol conjugates on zebrafish pigmentation. Le HT; Hong BN; Lee YR; Cheon JH; Kang TH; Kim TW Bioorg Med Chem Lett; 2016 Jan; 26(2):699-705. PubMed ID: 26684849 [TBL] [Abstract][Full Text] [Related]
14. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541 [TBL] [Abstract][Full Text] [Related]
15. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma. Monheit GD; Dreher F J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. Dar NR; Shaheen ; Mustafvi SA; Raza N J Coll Physicians Surg Pak; 2005 Aug; 15(8):496-7. PubMed ID: 16202363 [TBL] [Abstract][Full Text] [Related]
17. Hydroquinone-induced depigmentation: case report and review of the literature. Jow T; Hantash BM Dermatitis; 2014; 25(1):e1-5. PubMed ID: 24407054 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022 [TBL] [Abstract][Full Text] [Related]
19. Risk assessment of skin lightening cosmetics containing hydroquinone. Matsumoto M; Todo H; Akiyama T; Hirata-Koizumi M; Sugibayashi K; Ikarashi Y; Ono A; Hirose A; Yokoyama K Regul Toxicol Pharmacol; 2016 Nov; 81():128-135. PubMed ID: 27521610 [TBL] [Abstract][Full Text] [Related]
20. Methylation and Esterification of Magnolol for Ameliorating Cutaneous Targeting and Therapeutic Index by Topical Application. Lin CF; Hung CF; Aljuffali IA; Huang YL; Liao WC; Fang JY Pharm Res; 2016 Sep; 33(9):2152-67. PubMed ID: 27233503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]